V938
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
November 04, 2022
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1 | N=35 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Completed ➔ Terminated; Business Reasons
Combination therapy • Trial termination • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1
September 06, 2022
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1 | N=35 | Completed | Sponsor: Merck Sharp & Dohme LLC | Active, not recruiting ➔ Completed
Combination therapy • Trial completion • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1
June 10, 2022
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1 | N=35 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | N=84 ➔ 35
Combination therapy • Enrollment change • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1
May 23, 2022
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1 | N=84 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2022 ➔ Aug 2022 | Trial primary completion date: Dec 2022 ➔ Aug 2022
Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1
December 16, 2021
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1; N=84; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Jul 2022 ➔ Dec 2022; Trial primary completion date: Jul 2022 ➔ Dec 2022
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PCR • PD-L1
October 11, 2021
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
(clinicaltrials.gov)
- P1; N=84; Recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Jan 2024 ➔ Jul 2022; Trial primary completion date: Jan 2024 ➔ Jul 2022
Clinical • Combination therapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PCR • PD-L1
1 to 6
Of
6
Go to page
1